Managed care pharmacists and other stakeholders tasked with assessing the clinical value of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy may want to heed a new study showing that earlier treatment with evolocumab (Repatha, Amgen) in adults with atherosclerosis lowered the incidence of major cardiovascular (CV) events, including death.
The data come from the phase 3 FOURIER-OLE trials, which evaluated 6,635 patients from the FOURIER parent study